A method for treating damaged or diseased mammalian tissue that includes the steps of (i) providing a sheet structure formed from acellular dermal mammalian tissue that includes extracellular matrix (ECM) and a supplemental bioactive component, such as a nucleic acid, and/or a cell, and (ii) delivering the sheet structure to the damaged or diseased mammalian tissue, wherein the sheet structure induces angiogenesis and, thereby, regeneration of new mammalian tissue.

The invention provides compositions and methods for ameliorating symptoms associated with hyperglycemia by administering a Zn-α2-glycoprotein or a functional fragment thereof, methods of decreasing plasma insulin levels, methods of increasing skeletal muscle mass, and methods of bringing about a weight reduction or reduction in obesity, Also provided are pharmaceutical compositions for use thereof.

The present application relates to the field of glyco-engineering, more specifically to glycosylation-engineered fungal cells, more specifically glycosylation-engineered yeast cells, optimized to produce highly homogenous forms of complex N-glycans on recombinant proteins. The invention specifically relates to methods to obtain pharmaceutical compositions comprising recombinant glycoproteins which have homogenous forms of complex N-glycans. In addition, the invention relates to novel pharmaceutical compositions which result from the methods of the invention.

The present application relates to the administration of plasma, fractions thereof, or mixtures thereof to humans or animals to treat or otherwise improve cognitive impairment disorders, including dementia (e.g., vascular dementia, dementia with Lewy bodies, dementia resulting from Alzheimer's disease, dementia resulting from Parkinson's disease, frontotemporal dementia, and dementia resulting from normal pressure hydrocephalus in humans, and cognitive dysfunction syndrome in companion animals), concussion, and traumatic brain injury, in certain embodiments, the invention comprises a method of treating a cognitive impairment disorder in a human or companion animal subject, said method comprising: administering to said subject one or more cognitive functioning tests to identify a subject suffering from a cognitive impairment disorder; and administering to said subject a therapeutically effective amount of an animal plasma composition; wherein said administration provides an improvement in said subject's results in said one or more cognitive impairment tests.

Novel artificial exosomes and methods for producing novel artificial exosomes are provided. Methods of delivering cargo molecules to a cell using artificial exosomes are also provided.

The present disclosure provides a panel of biomarkers for use in diagnosing and/or monitoring kidney health during a therapeutic treatment for a therapeutic regimen that induces renal impairment or chronic kidney disease. Such monitoring may be useful in subjects undergoing treatment a disease such as diabetes mellitus and/or hypertension, where a therapeutic regimen results in increased levels of blood creatinine.

An application of a skeletal muscle secreted factor Thbs4 in a preparation of a drug for improving systemic glucose and lipid metabolism is provided. According to the present invention, it is found through experiments that Thbs4 increases a body's metabolic rate by activating a beige-like change of white adipose, relieves the metabolic disorder caused by high-fat diet, and reveals its application value in the treatment of the metabolic disorder.

A protein that is at least one SUMO protein, or a variant or a fragment thereof or a fusion protein including a SUMO protein is for use in the treatment of neurodegenerative and/or neurological disorders. A pharmaceutical composition includes a protein that is at least one SUMO protein or a variant or a fragment thereof or a fusion protein including a SUMO protein and pharmaceutically acceptable carriers.

The present invention provides modified von Willebrand Factor molecules, methods for their preparation and uses thereof. The invention further provides pharmaceutical compositions for treating coagulation disorders.

The invention relates to aortopathy, and in particular, to compositions and methods for the diagnosis and treatment of aortopathy.